FDA Approves New Parkinson's Drug Tavapadon

The U.S. Food and Drug Administration (FDA) has approved tavapadon (brand name Juvmo), a once-daily oral medicine for adults with Parkinson's disease. This drug is a selective dopamine D1/D5 receptor partial agonist, offering a new treatment option that differs from traditional dopamine agonists by selectively targeting specific dopamine receptors. It has been studied as both an early treatment and alongside levodopa in patients with more advanced Parkinson's disease.